The approval was supported by 3 P-II studies assessing the safety & efficacy of Enhertu incl. DESTINY-PanTumor02 (5.4mg/kg) for HER2-expressing tumors, DESTINY-Lung01 (5.4mg/kg or 6.4mg/kg) for HER2m or HER2-overexpressing inoperable/metastatic non-squamous NSCLC & DESTINY-CRC02 (5.4mg/kg or 6.4mg/kg) for locally advanced, unresectable or metastatic HER2+ colorectal cancer
A confirmed ORR of 51.4%, 52.9% & 46.9% while mDoR of 19.4mos., 6.9mos. & 5.5mos. was observed in the DESTINY-PanTumor02, DESTINY-Lung01 & DESTINY-CRC02 studies, respectively
On the basis of these results, Enhertu has been added to the NCCN guidelines for the treatment of various metastatic tumors
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca and Daiichi Sankyo Reports sBLA Acceptance with Priority Review by the US FDA for Enhertu to Treat HER2-Expressing Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
